Daisy Robinton, Ph.D. is singularly focused on a quest to extend ovarian health and longevity and advocate for all women’s health.
Ovaries age faster than other tissues in the body, such as the kidney or the heart. Understanding how to slow the ovary’s aging process may unlock longevity and health insights beyond the organ itself. Robinton and her team developed OVI-586, a therapeutic designed to preserve and prolong ovarian function. Her persistence has paid off — the company she co-founded, Oviva Therapeutics, was acquired by biopharmaceutical company Granata Bio this past month.
Robinton’s drive was evident early. After completing her undergraduate degree at UCLA, Robinton earned a Ph.D. in Human Biology and Translational Medicine at Harvard University, where she founded the Science in the News Spring Public Lecture Series. As a Postdoctoral Fellow at Harvard, she earned a spot on Forbes’ 30 under 30: Science List, having published papers on stem cell research and liver cancer. She also co-founded her first company, Weird and Wonderful, a production company blending arts with sciences.
An expert on aging, Robinton has delivered two TEDx talks, one discussing how genetic engineering may be harnessed to slow the aging process, and the second exploring how mindset can affect aging. “I believe we can engineer resilience to aging,” she says. Robinton also serves as a scientific advisory board member for Parfums Christian Dior, SHE Media’s women’s health platform, Flow Space, and is an XPRIZE technical consultant for the upcoming women’s health XPRIZE focused on understanding and improving ovarian function.
We are thrilled that Dr. Robinton is joining the DOC 2025 Faculty, and hope you’ll join us in welcoming her to Napa this fall.